Detailed Mechanism Funding and Narrative

Years of mechanism: 2010 2011 2012 2013 2014 2015 2016 2017 2018

Details for Mechanism ID: 10000
Country/Region: Vietnam
Year: 2018
Main Partner: Harvard University
Main Partner Program: Harvard Medical School (Harvard Medical School AIDS Initiative in Vietnam)
Organizational Type: University
Funding Agency: HHS/CDC
Total Funding: $726,851 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $0
Care: Orphans and Vulnerable Children (HKID) $0
Care: TB/HIV (HVTB) $0
Care: Pediatric Care and Support (PDCS) $0
Laboratory Infrastructure (HLAB) $0
Strategic Information (HVSI) $0
Health Systems Strengthening (OHSS) $0
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $0
Biomedical Prevention: Blood Safety (HMBL) $0
Biomedical Prevention: Injection Safety (HMIN) $0
Sexual Prevention: Abstinence/Be Faithful (HVAB) $0
Testing: HIV Testing and Counseling (HVCT) $0
Sexual Prevention: Other Sexual Prevention (HVOP) $0
Prevention: Injecting and Non-Injecting Drug Use (IDUP) $0
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $0
Treatment: ARV Drugs (HTXD) $0
Treatment: Adult Treatment (HTXS) $726,851
Treatment: Pediatric Treatment (PDTX) $0
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
TB_PREV By Age/Sex (Numerator): <15, Female 2019 19
TB_PREV By Age/Sex (Numerator): <15, Male 2019 19
TB_PREV By Age/Sex (Numerator): 15+, Female 2019 390
TB_PREV By Age/Sex (Numerator): 15+, Male 2019 728
TB_PREV The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period 2019 1,156
TB_PREV The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period) 2019 1,361
TB_PREV_den By Age/Sex (Denominator): <15, Female 2019 21
TB_PREV_den By Age/Sex (Denominator): <15, Male 2019 21
TB_PREV_den By Age/Sex (Denominator): 15+, Female 2019 461
TB_PREV_den By Age/Sex (Denominator): 15+, Male 2019 858
TX_CURR 25-29, Female, Positive 2019 1,489
TX_CURR 25-29, Male, Positive 2019 2,817
TX_CURR 30-34, Female, Positive 2019 1,326
TX_CURR 30-34, Male, Positive 2019 2,653
TX_CURR 35-39, Female, Positive 2019 662
TX_CURR 35-39, Male, Positive 2019 1,326
TX_CURR 40-49, Female, Positive 2019 331
TX_CURR 40-49, Male, Positive 2019 331
TX_CURR Age/Sex: 1-9 2019 452
TX_CURR Age/Sex: 10-14 Female 2019 226
TX_CURR Age/Sex: 10-14 Male 2019 225
TX_CURR Age/Sex: 15-19 Female 2019 331
TX_CURR Age/Sex: 15-19 Male 2019 496
TX_CURR Age/Sex: 20-24 Female 2019 1,489
TX_CURR Age/Sex: 20-24 Male 2019 2,982
TX_CURR Age/Sex: 50+ Female 2019 167
TX_CURR Age/Sex: 50+ Male 2019 169
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2019 17,472
TX_CURR Sum of Age/Sex disaggregations 2019 827
TX_NEW 25-29, Female, Positive 2019 329
TX_NEW 25-29, Male, Positive 2019 623
TX_NEW 30-34, Female, Positive 2019 293
TX_NEW 30-34, Male, Positive 2019 585
TX_NEW 35-39, Female, Positive 2019 145
TX_NEW 35-39, Male, Positive 2019 293
TX_NEW 40-49, Female, Positive 2019 77
TX_NEW 40-49, Male, Positive 2019 77
TX_NEW By Age/Sex: 1-9 2019 25
TX_NEW By Age/Sex: 10-14 Female 2019 11
TX_NEW By Age/Sex: 10-14 Male 2019 9
TX_NEW By Age/Sex: 15-19 Female 2019 77
TX_NEW By Age/Sex: 15-19 Male 2019 112
TX_NEW By Age/Sex: 20-24 Female 2019 329
TX_NEW By Age/Sex: 20-24 Male 2019 661
TX_NEW By Age/Sex: 50+ Female 2019 36
TX_NEW By Age/Sex: 50+ Male 2019 34
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2019 3,716
TX_NEW Sum of Age/Sex disaggregates 2019 1,269
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2019 16,610
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Routine 2019 256
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Routine 2019 256
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine 2019 5,631
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine 2019 10,467
TX_PVLS_den Denominator: Indication: Routine 2019 16,610
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 29
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 522
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 27
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 973
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2019 1,551
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2019 1,725
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 32
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 583
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 29
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 1,081
TX_TB Number of ART patients who were screened for TB at least once during the reporting period 2019 15,730
TX_TB Number of ART patients who were started on TB treatment during the reporting period 2019 234
TX_TB Numerator: By Aggregated Age/Sex: 15+, Female 2019 80
TX_TB Numerator: By Aggregated Age/Sex: 15+, Male 2019 154
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Female 2019 245
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Male 2019 245
TX_TB_den Denominator: By Aggregated Age/Sex: 15+, Female 2019 5,334
TX_TB_den Denominator: By Aggregated Age/Sex: 15+, Male 2019 9,906